619 related articles for article (PubMed ID: 17431118)
21. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.
Pene-Dumitrescu T; Peterson LF; Donato NJ; Smithgall TE
Oncogene; 2008 Nov; 27(56):7055-69. PubMed ID: 18794796
[TBL] [Abstract][Full Text] [Related]
22. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
Lin H; Chen M; Rothe K; Lorenzi MV; Woolfson A; Jiang X
Oncotarget; 2014 Sep; 5(18):8637-50. PubMed ID: 25226617
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
24. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Quintás-Cardama A; Kantarjian H; Cortes J
Future Oncol; 2006 Dec; 2(6):655-65. PubMed ID: 17155893
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
26. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Mahon FX; Hayette S; Lagarde V; Belloc F; Turcq B; Nicolini F; Belanger C; Manley PW; Leroy C; Etienne G; Roche S; Pasquet JM
Cancer Res; 2008 Dec; 68(23):9809-16. PubMed ID: 19047160
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
Copland M; Hamilton A; Elrick LJ; Baird JW; Allan EK; Jordanides N; Barow M; Mountford JC; Holyoake TL
Blood; 2006 Jun; 107(11):4532-9. PubMed ID: 16469872
[TBL] [Abstract][Full Text] [Related]
28. Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line.
Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
J Hematol Oncol; 2011 Aug; 4(1):32. PubMed ID: 21806844
[TBL] [Abstract][Full Text] [Related]
29. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
Cheng Y; Hao Y; Zhang A; Hu C; Jiang X; Wu Q; Xu X
Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375
[TBL] [Abstract][Full Text] [Related]
30. Dasatinib: BMS 354825.
Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib: a new step in molecular target therapy.
Olivieri A; Manzione L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi42-6. PubMed ID: 17591830
[TBL] [Abstract][Full Text] [Related]
32. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
[TBL] [Abstract][Full Text] [Related]
33. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
[TBL] [Abstract][Full Text] [Related]
34. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
[TBL] [Abstract][Full Text] [Related]
35. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
[TBL] [Abstract][Full Text] [Related]
36. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
Okabe S; Tauchi T; Katagiri S; Tanaka Y; Ohyashiki K
J Hematol Oncol; 2014 Apr; 7():37. PubMed ID: 24775308
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
McCormack PL; Keam SJ
Drugs; 2011 Sep; 71(13):1771-95. PubMed ID: 21902298
[TBL] [Abstract][Full Text] [Related]
38. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.
Dumka D; Puri P; Carayol N; Lumby C; Balachandran H; Schuster K; Verma AK; Terada LS; Platanias LC; Parmar S
Leuk Lymphoma; 2009 Dec; 50(12):2017-29. PubMed ID: 19672773
[TBL] [Abstract][Full Text] [Related]
39. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
Nelson EA; Walker SR; Weisberg E; Bar-Natan M; Barrett R; Gashin LB; Terrell S; Klitgaard JL; Santo L; Addorio MR; Ebert BL; Griffin JD; Frank DA
Blood; 2011 Mar; 117(12):3421-9. PubMed ID: 21233313
[TBL] [Abstract][Full Text] [Related]
40. PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.
Wu N; Kurosu T; Oshikawa G; Nagao T; Miura O
Int J Oncol; 2013 Feb; 42(2):419-28. PubMed ID: 23233201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
